vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.3%, a 9.0% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs -1.8%). ALBANY INTERNATIONAL CORP produced more free cash flow last quarter ($51.4M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AIN vs AMPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $183.1M |
| Net Profit | $13.9M | $24.4M |
| Gross Margin | 31.1% | 46.8% |
| Operating Margin | 9.3% | 19.4% |
| Net Margin | 4.3% | 13.3% |
| Revenue YoY | 12.0% | -1.8% |
| Net Profit YoY | -21.5% | -35.7% |
| EPS (diluted) | $0.56 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $183.1M | ||
| Q3 25 | $261.4M | $191.8M | ||
| Q2 25 | $311.4M | $174.4M | ||
| Q1 25 | $288.8M | $170.5M | ||
| Q4 24 | $286.9M | $186.5M | ||
| Q3 24 | $298.4M | $191.2M | ||
| Q2 24 | $332.0M | $182.4M | ||
| Q1 24 | $313.3M | $171.8M |
| Q4 25 | $13.9M | $24.4M | ||
| Q3 25 | $-97.8M | $17.4M | ||
| Q2 25 | $9.2M | $31.0M | ||
| Q1 25 | $17.4M | $25.3M | ||
| Q4 24 | $17.7M | $38.0M | ||
| Q3 24 | $18.0M | $40.4M | ||
| Q2 24 | $24.6M | $37.9M | ||
| Q1 24 | $27.3M | $43.2M |
| Q4 25 | 31.1% | 46.8% | ||
| Q3 25 | -19.1% | 51.4% | ||
| Q2 25 | 31.3% | 49.6% | ||
| Q1 25 | 33.4% | 50.0% | ||
| Q4 24 | 31.5% | 46.5% | ||
| Q3 24 | 30.3% | 53.3% | ||
| Q2 24 | 33.9% | 52.2% | ||
| Q1 24 | 34.7% | 52.4% |
| Q4 25 | 9.3% | 19.4% | ||
| Q3 25 | -44.6% | 13.2% | ||
| Q2 25 | 7.2% | 24.2% | ||
| Q1 25 | 9.8% | 21.9% | ||
| Q4 24 | 8.5% | 24.2% | ||
| Q3 24 | 8.4% | 29.8% | ||
| Q2 24 | 12.9% | 30.3% | ||
| Q1 24 | 12.4% | 27.9% |
| Q4 25 | 4.3% | 13.3% | ||
| Q3 25 | -37.4% | 9.0% | ||
| Q2 25 | 2.9% | 17.8% | ||
| Q1 25 | 6.0% | 14.8% | ||
| Q4 24 | 6.2% | 20.4% | ||
| Q3 24 | 6.0% | 21.1% | ||
| Q2 24 | 7.4% | 20.8% | ||
| Q1 24 | 8.7% | 25.1% |
| Q4 25 | $0.56 | $0.51 | ||
| Q3 25 | $-3.37 | $0.37 | ||
| Q2 25 | $0.31 | $0.64 | ||
| Q1 25 | $0.56 | $0.51 | ||
| Q4 24 | $0.57 | $0.74 | ||
| Q3 24 | $0.57 | $0.78 | ||
| Q2 24 | $0.79 | $0.73 | ||
| Q1 24 | $0.87 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $282.8M |
| Total DebtLower is stronger | $455.7M | $608.7M |
| Stockholders' EquityBook value | $726.2M | $788.8M |
| Total Assets | $1.7B | $1.6B |
| Debt / EquityLower = less leverage | 0.63× | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $282.8M | ||
| Q3 25 | $108.3M | $276.2M | ||
| Q2 25 | $106.7M | $231.8M | ||
| Q1 25 | $119.4M | $236.9M | ||
| Q4 24 | $115.3M | $221.6M | ||
| Q3 24 | $127.2M | $250.5M | ||
| Q2 24 | $116.4M | $217.8M | ||
| Q1 24 | $125.4M | $289.6M |
| Q4 25 | $455.7M | $608.7M | ||
| Q3 25 | $480.6M | $608.6M | ||
| Q2 25 | $444.7M | $607.7M | ||
| Q1 25 | $416.4M | $603.9M | ||
| Q4 24 | $318.5M | $601.6M | ||
| Q3 24 | $362.2M | $596.4M | ||
| Q2 24 | $377.1M | $586.9M | ||
| Q1 24 | $439.1M | $594.0M |
| Q4 25 | $726.2M | $788.8M | ||
| Q3 25 | $739.3M | $776.7M | ||
| Q2 25 | $888.6M | $757.5M | ||
| Q1 25 | $900.0M | $751.3M | ||
| Q4 24 | $943.5M | $732.3M | ||
| Q3 24 | $991.0M | $727.7M | ||
| Q2 24 | $967.5M | $713.3M | ||
| Q1 24 | $967.5M | $672.4M |
| Q4 25 | $1.7B | $1.6B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.6B | ||
| Q1 25 | $1.7B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.5B | ||
| Q1 24 | $1.8B | $1.6B |
| Q4 25 | 0.63× | 0.77× | ||
| Q3 25 | 0.65× | 0.78× | ||
| Q2 25 | 0.50× | 0.80× | ||
| Q1 25 | 0.46× | 0.80× | ||
| Q4 24 | 0.34× | 0.82× | ||
| Q3 24 | 0.37× | 0.82× | ||
| Q2 24 | 0.39× | 0.82× | ||
| Q1 24 | 0.45× | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $32.9M |
| Free Cash FlowOCF − Capex | $51.4M | $24.6M |
| FCF MarginFCF / Revenue | 16.0% | 13.4% |
| Capex IntensityCapex / Revenue | 6.9% | 4.5% |
| Cash ConversionOCF / Net Profit | 5.31× | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $32.9M | ||
| Q3 25 | $43.9M | $52.6M | ||
| Q2 25 | $32.7M | $35.6M | ||
| Q1 25 | $2.1M | $35.1M | ||
| Q4 24 | $78.5M | $29.0M | ||
| Q3 24 | $47.0M | $60.0M | ||
| Q2 24 | $83.4M | $69.1M | ||
| Q1 24 | $9.6M | $55.3M |
| Q4 25 | $51.4M | $24.6M | ||
| Q3 25 | $25.9M | $47.2M | ||
| Q2 25 | $18.8M | $25.0M | ||
| Q1 25 | $-13.5M | $24.4M | ||
| Q4 24 | $60.2M | $16.6M | ||
| Q3 24 | $31.6M | $46.2M | ||
| Q2 24 | $63.6M | $63.1M | ||
| Q1 24 | $-17.3M | $46.5M |
| Q4 25 | 16.0% | 13.4% | ||
| Q3 25 | 9.9% | 24.6% | ||
| Q2 25 | 6.0% | 14.3% | ||
| Q1 25 | -4.7% | 14.3% | ||
| Q4 24 | 21.0% | 8.9% | ||
| Q3 24 | 10.6% | 24.1% | ||
| Q2 24 | 19.2% | 34.6% | ||
| Q1 24 | -5.5% | 27.1% |
| Q4 25 | 6.9% | 4.5% | ||
| Q3 25 | 6.9% | 2.8% | ||
| Q2 25 | 4.5% | 6.1% | ||
| Q1 25 | 5.4% | 6.3% | ||
| Q4 24 | 6.4% | 6.7% | ||
| Q3 24 | 5.2% | 7.2% | ||
| Q2 24 | 6.0% | 3.3% | ||
| Q1 24 | 8.6% | 5.1% |
| Q4 25 | 5.31× | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | 3.56× | 1.15× | ||
| Q1 25 | 0.12× | 1.39× | ||
| Q4 24 | 4.44× | 0.76× | ||
| Q3 24 | 2.61× | 1.48× | ||
| Q2 24 | 3.39× | 1.82× | ||
| Q1 24 | 0.35× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
